| SAN
DIEGO, April 27 /PRNewswire-FirstCall/ -- Nanogen,
Inc. (Nasdaq: NGEN ),
developer of advanced diagnostic products, announced
today that it has been issued European Patent No.
0943158B1, "Affinity Based Self-Assembly Systems
and Devices for Photonic and Electronic Applications," by
the European Patent Office. This patent is similar
to U.S. Patent 6,652,808, the parent of a series
of patent applications that significantly broaden
Nanogen's proprietary position in the nanotechnology
and nanomanufacturing areas. The U.S. patent was
issued in December 2003.
The new nanotechnology patent
relates to a nanofabrication technology that combines
an electric field assisted manufacturing platform
and programmable self-assembling nanostructures
(for example, DNA building blocks) for the fabrication
of a wide range of unique higher-order nano and
microscale devices, structures and materials. The
nanofabrication platform and process would be used
for: producing nanoscale electronic and photonic
devices and structures; assembly of nanostructures
and submicron components onto silicon wafers and
other materials; integration of nanostructures within
preformed microelectronic and optoelectronic structures;
production of nanoparticles (for example, photonic
crystals, nanospheres and quantum dots); and fabrication
of selectively addressable DNA nanoarray substrates
and materials.
The patent represents a unique nanofabrication
technology that combines the best aspects of top-down
microfabrication processes with bottom-up biological
self-assembly processes for producing novel nanodevices
and nanostructures. The European patent is jointly
owned by Nanotronics, Inc., a wholly owned subsidiary
of Nanogen, and the Regents of the University of
California. Nanogen has exclusively licensed the
interests of the University of California where
there is joint inventorship.
About Nanogen, Inc.
Nanogen's advanced diagnostics provide physicians
and patients worldwide with sophisticated information
to predict, diagnose and treat disease. Research
and clinical reference labs use the highly accurate
and reliable NanoChip(R) Molecular Biology Workstation,
NanoChip(R) Electronic Microarray and broad suite
of analyte specific reagents to develop diagnostic
tests for variety of diseases. Nanogen also offers
a broad portfolio of patented nucleic acids chemistries
and molecular tools that accelerate genomic analysis
and are compatible with many systems. The SynX
subsidiary offers a line of point-of-care diagnostic
tests and is building expertise in cardiac related
health conditions. Nanogen's ten years of pioneering
research involving nanotechnology may also have
future applications in medical diagnostics, biowarfare
and other industries.
For additional information
please visit Nanogen's website at http://www.nanogen.com .
SOURCE Nanogen, Inc.
Web Site: http://www.nanogen.com
|
